Paul V. Campanelli
Paul V. Campanelli is President, Chief Executive Officer and a Director of Endo International plc. Mr. Campanelli joined Endo in 2015 as the President of Par Pharmaceutical, leading Endo’s fully integrated U.S. Generics business, following Endo’s acquisition of Par Pharmaceutical. Prior to joining Endo, Paul had served as Chief Executive Officer of Par Pharmaceutical Companies, Inc. following the company’s September 2012 acquisition by TPG. While CEO of Par, Mr. Campanelli built a strong leadership team and an industry-leading generics business. Under his leadership, the company significantly increased total revenue, acquired Michigan-based JHP Pharmaceuticals, established a business office in London to serve as Par’s entry point into the European generics market and completed its acquisition of an active pharmaceutical ingredients (API) facility located in Chennai, India. Prior to the TPG acquisition, Paul served as Chief Operating Officer and President of Par Pharmaceutical, Inc., the company’s generics division, from 2011 to 2012. Earlier in his tenure at Par, Mr. Campanelli held roles of increasing responsibility, including Senior Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by Par’s board of directors. He also served on the board of directors of Sky Growth Holdings Corporation. Prior to joining Par, Mr. Campanelli served as Vice President, Business Development at Dr. Reddy’s Laboratories Ltd. where he was employed from 1992-2001. He earned his Bachelor of Science degree from Springfield College.
Joseph J. Ciaffoni
Joseph J. Ciaffoni joined Endo as President, U.S. Branded Pharmaceuticals in August 2016. In his role, Mr. Ciaffoni leads Endo’s U.S. Branded Pharmaceutical business, driving the development and execution of Endo’s branded strategy and accelerating key growth drivers. His extensive industry experience includes building commercial businesses, leading multi-function organizations and achieving significant results across primary care, specialty and rare disease markets. Prior to joining Endo, Mr. Ciaffoni served as Senior Vice President, Global Specialty Medicines Group for Biogen where he led the development and execution of all aspects of global strategy across the value chain for marketed and pipeline products. Mr. Ciaffoni joined Biogen Idec in 2012 and during his tenure also held senior roles including Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen, Mr. Ciaffoni was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Previously, he served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Mr. Ciaffoni holds a B.A. in Communications and an M.B.A. from Rutgers, The State University of New Jersey.
Susan Hall, Ph.D.
Susan Hall, Ph.D. was appointed as Executive Vice President, Chief Scientific Officer and Global Head of Research & Development and Quality in March 2014. Dr. Hall is based in Dublin, Ireland at Endo’s global corporate headquarters. Prior to joining Endo, Dr. Hall served as Senior Vice President and Global Head of Research and Development at Valeant Pharmaceuticals International, Inc. In this position, she led the company’s product pipeline and life cycle management activities and also had responsibility for quality compliance. In addition, Dr. Hall has also held various leadership roles in research & development at GlaxoSmithKline including clinical pharmacology, project management, medical affairs, and regulatory affairs. Dr. Hall holds a B.S. degree in pharmacology from the University of Leeds (U.K.) and a Ph.D. in Pharmacokinetics from the Department of Pharmacy, University of Manchester (U.K.).
Matthew J. Maletta
Matthew J. Maletta was appointed Executive Vice President, Chief Legal Officer effective May 4, 2015. He brings to his role nearly two decades of legal experience in the specialty pharmaceutical industry and with private law firms, including extensive experience in M&A, corporate, securities, finance, commercial and employment law. Prior to joining Endo, Mr. Maletta served as Vice President, Associate General Counsel and Corporate Secretary of Allergan, Inc. In this position, he served as an advisor to the CEO and Board of Directors and supervised several large M&A transactions and takeover defense activities, including Allergan’s acquisition of Inamed and Actavis’ acquisition of Allergan. Mr. Maletta first joined Allergan in 2002 as Corporate Counsel and Assistant Secretary and during his tenure, held various roles of increased responsibility. He had a key role negotiating Allergan’s Corporate Integrity Agreement with the Department of Justice, served as the lead commercial attorney for the Allergan medical businesses and served as Interim Head of Human Resources. Prior to joining Allergan, Mr. Maletta was in private practice, focusing on general corporate matters, finance, governance, securities and transactions. He holds a B.A. degree in political science from the University of Minnesota, summa cum laude, and a J.D. degree, cum laude, from the University of Minnesota Law School. From 2012 – 2015, Mr. Maletta served as a member of the Board of Directors of United Cerebral Palsy – Orange County (UCP) and co-chaired UCP’s annual “Life Without Limits” galas in 2012, 2013 and 2015.
Dan A. Rudio
Daniel A. Rudio was appointed Vice President, Controller and Chief Accounting Officer effective April 1, 2011. Mr. Rudio joined Endo in November 2006 as Financial Reporting Manager and has held various positions of increasing responsibility. Prior to joining the Company, Mr. Rudio was a finance manager at Rohm and Haas Company where he worked for four years in a variety of accounting and finance positions of increasing responsibility. Mr. Rudio began his career in public accounting at Ernst & Young LLP where he worked from July 1995 to November 2002. Mr. Rudio is a licensed certified public accountant in the Commonwealth of Pennsylvania and holds Bachelors of Science degrees in both accounting and finance from Rutgers University.
Suketu “Suky” Upadhyay, Executive Vice President and Chief Financial Officer, joined Endo in September 2013. Prior to joining Endo, since 2010, Mr. Upadhyay served as Interim Chief Financial Officer as well as Senior Vice President of Finance and Corporate Controller of Becton, Dickinson & Co (BD). In addition to other executive finance roles at BD, from 2007 to 2010, he served in various finance leadership roles at AstraZeneca and Johnson & Johnson. Mr. Upadhyay spent the early part of his career in public accounting with KPMG and received his CPA in May 1996. He received a Bachelor of Science in Finance from Albright College and received a Master of Business Administration from The Fuqua School of Business at Duke University.
Hemanth J. Varghese, Ph.D.
Hemanth J. Varghese, Ph.D. serves as President, International Pharmaceuticals and Executive Vice President, Corporate Development at Endo. In this role, he has global responsibility for leading Endo’s International Pharmaceuticals businesses, in addition to leading the company’s global acquisitions and integration efforts. He works closely with Endo’s International leadership team to strengthen and expand the Company’s operations in Ireland, Canada, Latin America and South Africa while advancing business opportunities in new international markets. Dr. Varghese is based in Dublin, Ireland at Endo’s global corporate headquarters. He joined Endo in 2014 and most recently served as Executive Vice President, Corporate Development & Strategy. Prior to Endo, he served as the Senior Vice President and General Manager of Vision Care for Bausch & Lomb, a division of Valeant Pharmaceuticals. Over his career he has completed more than 40 corporate transactions, leading corporate development and integration initiatives including public/private acquisitions, investments, partnerships, licenses and divestitures. Earlier in his career, Dr. Varghese served in corporate development and operations leadership roles at Biovail Corporation, JovInvestment Management Inc., and Robarts Research Institute. He obtained his BSc degree with honors in Biophysics and PhD in Medical Biophysics from the University of Western Ontario and holds the Charted Financial Analyst ® designation.
Robert J. Cobuzzi Jr., Ph. D.
Robert J. Cobuzzi Jr. is President, Endo Ventures Limited based in Dublin, Ireland. Dr. Cobuzzi joined Endo in 2005 and has held the positions of Senior Vice President, Corporate Development and most recently, Senior Vice President, R&D Strategy and Operations. Before joining Endo, he held management positions in clinical development and licensing at Adolor Corporation. Prior to Adolor, Dr. Cobuzzi gained extensive experience in global regulatory affairs and biologics at Centocor/Johnson & Johnson, and in clinical development at AstraMerck in the areas of thrombosis and hypertension. Dr. Cobuzzi received his Ph.D. in molecular and cellular biochemistry from Loyola University Chicago, and a Bachelor of Arts degree with majors in biochemistry and art history from Colby College. He completed a post-doctoral fellowship in the Department of Experimental Therapeutics at Roswell Park Cancer Institute. He previously served as a member of the U.S. Department of Commerce and the Office of the U.S. Trade Representative’s Industry Trade Advisory Committee on Chemicals, Pharmaceuticals, Health/Science Products and Services. He currently serves as a member of Sunstone Capital’s Business Development Advisory Board, and as a member of the Science and Technology Advisory Board of the Children’s Hospital of Philadelphia.
Larry Cunningham, Executive Vice President, Human Resources, joined Endo in May 2008. In this role he leads all aspects of human resources in enabling the development and growth of Endo. Prior to joining Endo, Mr. Cunningham led Johnson & Johnson’s global recruiting and talent acquisition organization. Mr. Cunningham also has extensive business-based human resources leadership experience. He was Vice President, Human Resources, for DePuy, Inc., a wholly owned subsidiary of Johnson & Johnson, which he joined following the acquisition of Centocor, where he was Vice President, Human Resources. Prior to joining Centocor, Mr. Cunningham gained extensive domestic and international experience in human resources management and organization development at Rhone-Poulenc Rorer (now Sanofi-Aventis) and Corning Clinical Laboratories (now Quest Diagnostics). Mr. Cunningham holds a B.A. in Labor Studies from the Pennsylvania State University and a Master of Science in Business Administration from Temple University.
Jennifer E. Dubas
Jennifer E. Dubas is Senior Vice President and Chief Compliance Officer, effective October 2016. In this role, she is responsible for the strategic direction and operations of Endo’s corporate compliance program. Ms. Dubas joined Endo in 2011 and has been a valued member of Endo’s Legal leadership team, previously serving as Endo’s Senior Vice President, Associate General Counsel where she was responsible for managing all non-IP, non-employment litigation for Endo and its subsidiaries. In 2015, she accepted the additional responsibility of managing the legal support for Endo’s U.S. Branded Pharmaceutical business. In this role, in addition to advising the business on legal matters, Ms. Dubas also provided legal support to Endo’s Compliance organization, including the advising on the successful management of Endo’s 2014 Corporate Integrity Agreement (CIA) and Deferred Prosecution Agreement (DPA). She has spent her 16 year legal career providing effective advice to pharmaceutical, medical device and consumer products companies. Ms. Dubas began her professional career as an associate in Dechert’s litigation group where she represented various pharmaceutical and consumer product companies. In 2005, Ms. Dubas joined Wyeth’s in-house litigation team and then served in a similar capacity for Pfizer, following its acquisition of Wyeth. She holds a Juris Doctor degree, magna cum laude, from Temple University, and a Bachelor of Arts degree, magna cum laude, from Bryn Mawr College.
Keri P. Mattox
Keri P. Mattox joined Endo as Senior Vice President, Investor Relations & Corporate Affairs in February 2015. In her role, Keri is responsible for the development and implementation of the company’s comprehensive and strategic IR and corporate communications platform as well as Government Affairs efforts. Ms. Mattox brings more than 15 years of experience in strategic life sciences communications, investor relations and journalism to Endo. Most recently, she was Senior Vice President, Investor Relations and Corporate Communications for Auxilium Pharmaceuticals, Inc. Prior to Auxilium, she was Executive Vice President at Pure Communications, a life sciences communications firm where she managed all aspects of communications and IR strategy for publicly-traded and private company clients across the biotech and pharmaceuticals spectrum. Her clients have been featured on CNBC and in the Wall Street Journal, New York Times and Forbes. Prior to Pure, Ms. Mattox served as an independent communications consultant, the Director of Corporate Communications and Investor Relations for both NABI Biopharmaceuticals and DOV Pharmaceuticals and the Director of Science Marketing and Economic Development for the University of Pennsylvania. Previously, she was an Account Director at FitzGerald Communications in Boston and then Washington, D.C., where she headed up the agency’s life sciences initiatives.
Ms. Mattox began her career as a news and business reporter for Hearst Newspapers in New York and the Capital News Service in Washington, D.C. She holds a BA in Political Science from Boston University and an MA in Journalism from the University of Maryland.